First human tests begin for potential Alpha-1 treatment
NCT ID NCT03362242
Summary
This early-stage study tested the safety of an experimental drug called ARO-AAT in 45 healthy volunteers. Researchers wanted to understand how the body processes the drug and whether it affects levels of the Alpha-1 protein. The study focused on identifying side effects and determining safe dosage levels for future research.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALPHA 1-ANTITRYPSIN DEFICIENCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site 1
Grafton, Auckland, 1010, New Zealand
Conditions
Explore the condition pages connected to this study.